Pfizer Inc (PFE) announced an update on their ongoing clinical study.

The accepted paper, titled "Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study", will be presented in the Ocular Surface ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies ...

CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...

SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initia ...

Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt ...

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...

Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune ...

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to ...

SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will ...